Loading…
← CockpitCompetitor Analysis › 688166.SS BrightGene Bio-Medical Technology Co. Ltd. Class AOpen in the cockpit ↗

BrightGene Bio-Medical Technology Co. Ltd. Class A688166.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese maker of complex generic and peptide active pharmaceutical ingredients, including antiviral and specialty drug APIs.

Momentum laggard 5
Mkt cap
$1.71B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$35.5M
20-day average traded
Fwd P/E
74.9×
forward earnings
ROIC−WACC
-5.9 pp
WACC 9.3%
Hurdle
+26 pp
Req g minus delivered
Next earnings
127 days
25 Mar 2027
Close · CNYCN¥26.53
1D-1.7%
1W-12.3%
1M-16.3%
3M-36.6%
6M-57.5%
YTD-45.9%
1Y-52.4%
ATR %5.5%
52w lowhigh63.6% off high

What BrightGene Bio-Medical Technology does

Chinese maker of complex generic and peptide active pharmaceutical ingredients, including antiviral and specialty drug APIs.

Products and services

  • Peptide/complex generic APIs
  • Antiviral drug APIs

Customers

  • Pharma companies (API buyers)

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Complex generic/peptide API…

What could go right

  • Complex generic/peptide API demand

What could go wrong

  • API price competition
  • Customer concentration

Moat: narrow (process know-how). Specialized synthesis capability for complex generics and peptide APIs.

Headquarters: Suzhou, China · Employees: 1,196

Named competitors

BrightGene Bio-Medical Technology at a glance

Size BrightGene Bio-Medical Technology (688166.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.71B, the 1340th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.53 on 18 Nov 2026.

Performance Over six months the shares fell 57.5%, against +1.8% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 20 in its peer set.

Growth Revenue grew 13.8% over the last twelve months (peer median +6.6%); the operating margin is 7.1% (peer median 8.6%).

Valuation It trades at 74.9× forward earnings against a peer median of 19.4× (2nd most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 35% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 5.9 points below its cost of capital (9.3% WACC).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026Peer median 103688166.SS 43
Six months, rebased to 100: BrightGene Bio-Medical Technology against the median of its 20 peers (local-currency closes).

BrightGene Bio-Medical Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.34BCN¥1.22BCN¥1.28BCN¥1.18BCN¥1.02B
Revenue growth—-5%+9%+16%—
Gross profitCN¥823MCN¥570MCN¥695MCN¥621MCN¥604M
EBITDAn/aCN¥204MCN¥311MCN¥288MCN¥292M
Net incomeCN¥102MCN¥54.5MCN¥189MCN¥202MCN¥240M
Free cash flowCN¥158M-CN¥133M-CN¥25.8M-CN¥210M-CN¥372M
Capital expenditureCN¥278MCN¥453MCN¥257MCN¥404MCN¥727M
Total debtCN¥2.55BCN¥2.41BCN¥2.29BCN¥2.25BCN¥2.05B

Quarterly statements and history in the cockpit →

BrightGene Bio-Medical Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%0%+20%MAZEFAE300723NATCOPHARMCAPLIPOINT600993INDGN300357AGIO9989600664ETON3933000766688166.SS6-month return →1-month return →
Up and to the right = strong over both horizons. BrightGene Bio-Medical Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×FAE300723NATCOPHARMCAPLIPOINT600993INDGN30035799891681ETON3933301015ZYME688166.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. BrightGene Bio-Medical Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%FAE300723NATCOPHARM1681ETON688166.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. BrightGene Bio-Medical Technology is the large dot.

BrightGene Bio-Medical Technology competitors and peer comparison

Head to head with its named competitors (688166.SS vs 300199.SZ vs BANB.SW vs PPGN.SW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
BrightGene Bio-Medical Technology 688166.SS$1.71B-57%+14%7%74.9×35.3%
Hybio Pharmaceutical 300199.SZ$2.68B-8%+70%31%44.7×37.4%
Bachem BANB.SW$7.06B0%+5%19%32.4×n/a
PolyPeptide PPGN.SW$1.61B+7%+22%7%52.1×n/a

How BrightGene Bio-Medical Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

BrightGene Bio-Medical Technology against its 20 peers (data as of 18 Nov 2026)
Measure688166.SSPeer medianRank in peer set
1-month return-16.3%-0.3%5th lowest of 21
6-month return-57.5%+1.8%lowest of 20
Distance from 52-week high-63.6%-32.1%lowest of 21
Revenue growth (TTM)+13.8%+6.6%9th highest of 20
Operating margin7.1%8.6%8th lowest of 20
Forward P/E74.9×19.4×2nd most expensive of 17
Growth the price implies (Req g, 7 yrs)35.3%10.1%most demanding of 16
Growth delivered (Del g)+9.2%+8.2%8th highest of 16
Hurdle (Req g minus delivered)+26.1 pp-0.2 pp2nd most demanding of 16
ROIC minus cost of capital-5.9 pp-0.8 pp7th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%74.9×35.3%+9.2%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%n/an/an/a
Faes Farma FAE.MCSpain$1.71B+6%+32%14%17.4×3.7%+9.9%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%21.4×24.3%+15.7%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%17.0×-3.5%+6.8%
Indegene INDGN.NSIndia$1.69B+28%+36%12%29.5×31.4%+29.4%
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%26.3×18.4%+10.8%
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Shenzhen Hepalink Pharmaceutical 9989.HKHong Kong$1.78B-13%-1%8%8.7×-0.4%-0.2%
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%9.2×-14.9%+13.5%
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%n/a33.0%+0.9%
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%

Questions

Who are BrightGene Bio-Medical Technology's main competitors?
Named competitors: Hybio Pharmaceutical (300199.SZ), Bachem (BANB.SW), PolyPeptide Group (PPGN.SW). The cockpit's measured peer set (industry) also includes Maze Therapeutics (MAZE), Faes Farma (FAE.MC), ApicHope Pharmaceutical (300723.SZ), NATCO Pharma (NATCOPHARM.NS), Caplin Point Laboratories (CAPLIPOINT.NS), Mayinglong Pharmaceutical (600993.SS).
Is BrightGene Bio-Medical Technology expensive compared with its peers?
On forward p/e it trades at 74.9× against a peer median of 19.4×, 2nd most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 35% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has BrightGene Bio-Medical Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -57.5% against +1.8% for the median peer; over one year -52.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.